Ticker HubNasdaq

JANX

Janux Therapeutics, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS

Latest price

$16.69+0.18%

As of Oct 26, 2026, 4:01 PM EDT · Market data by Massive

Market cap

$1.0B

Volume

379.2K

Previous close

$16.66

Day range

$16.51 – $17.18

Listed

Jun 11, 2021

Coverage

1 article

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $16.85Latest interval $16.69

Newsroom

Latest JANX coverage

BiotechBusinessDec 4, 2024

The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics

On December 3, 2024, the company announced groundbreaking results for its lead drug candidate, JANX007, a tumor-activated T-cell engager targeting advanced-stage prostate cancer.

JANX

Company overview

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 113
Headquarters: SAN DIEGO, CA
CIK: 0001817713

Company website View advanced chart

SEC filings

No filing records are attached to this profile yet.

Browse EDGAR

Profile at a glance

Jun 11, 2021

Listed

113

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.